✦ LIBER ✦

Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial

✍ Scribed by Li Zhang; Shenglin Ma; Xiangqun Song; Baohui Han; Ying Cheng; Cheng Huang; Shujun Yang; Xiaoqing Liu; Yunpeng Liu; Shun Lu; Jie Wang; Shucai Zhang; Caicun Zhou; Xiangwei Zhang; Nobuya Hayashi; Mengzhao Wang

Book ID: 117786034
Publisher: The Lancet
Year: 2012
Tongue: English
Weight: 371 KB
Volume: 13
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(12)70117-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of sunitinib as maintenan

Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer

✍ Gervais, Radj; Hainsworth, John D.; Blais, Normand; Besse, Benjamin; Laskin, Jan 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 264 KB

Afatinib versus placebo for patients wit

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

✍ Vincent A Miller; Vera Hirsh; Jacques Cadranel; Yuh-Min Chen; Keunchil Park; San 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 373 KB

Quality of life in patients with advance

Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study

✍ Chandra P Belani; Thomas Brodowicz; Tudor E Ciuleanu; Maciej Krzakowski; Sung Hy 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 230 KB

Maintenance therapy with pemetrexed plus

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial

✍ Luis Paz-Ares; Filippo de Marinis; Mircea Dediu; Michael Thomas; Jean-Louis Pujo 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 244 KB

Rationale and Design of MARQUEE: A Phase

Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non–Small-Cell Lung Cancer

✍ Giorgio V. Scagliotti; Silvia Novello; Joan H. Schiller; Vera Hirsh; Lecia V. Se 📂 Article 📅 2012 🏛 CIG Media Group, LP. 🌐 English ⚖ 332 KB

O-192a SWOG 0023: A randomized phase III

O-192a SWOG 0023: A randomized phase III trial of cisplatin/etoposide(PE) plus radiation therapy followed by consolidation docetaxel then maintenance therapy with gefitinib or placebo in patients with locally advanced unresectable stage III non-small cell lung cancer (NSCLC)

✍ Kelly, K.; Gaspar, L.E.; Chanksy, K.; Albain, K.S.; Jett, J.; Ung, Y.; Crowley, 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 143 KB